InnoCare Pharma Reports Orelabrutinib Data Across Blood Cancers

InnoCare Pharma reported durable real-world outcomes in CLL/SLL and high response rates in preliminary Phase II chemo-free regimens for newly diagnosed MZL and frail DLBCL. Safety was described as manageable across the studies.